Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IPH 6101

Next Previous
Drug Profile

IPH 6101

Alternative Names: IPH-61; IPH-6101; NKp46-based NK cell engager; SAR-443579; SAR’579

Latest Information Update: 05 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Innate Pharma
  • Developer Innate Pharma; Sanofi
  • Class Antibodies; Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Acute myeloid leukaemia; Myelodysplastic syndromes; Precursor B-cell lymphoblastic leukaemia-lymphoma

Most Recent Events

  • 23 Apr 2025 Sanofi and Innate agrees to terminate the 2016 Agreement relates to IPH 6101
  • 12 Jul 2024 Phase-I/II clinical trials in Acute myeloid leukaemia (First-line therapy) in USA (IV) (EudraCT2023-509438-20) (NCT06508489)
  • 17 Jun 2024 Efficacy and adverse events data from a phase I/II trial in Acute myeloid leukemia released by Innate Pharma

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top